E7389 (Eribulin Mesylate) + Vinorelbine injection
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-Negative Breast Cancer
Conditions
HER2-Negative Breast Cancer, Triple Negative Breast Cancer, Breast Cancer, Cancer of Breast, Breast Tumors
Trial Timeline
Sep 26, 2013 → Jun 22, 2018
NCT ID
NCT02225470About E7389 (Eribulin Mesylate) + Vinorelbine injection
E7389 (Eribulin Mesylate) + Vinorelbine injection is a phase 3 stage product being developed by Eisai for HER2-Negative Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02225470. Target conditions include HER2-Negative Breast Cancer, Triple Negative Breast Cancer, Breast Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02225470 | Phase 3 | Completed |
Competing Products
19 competing products in HER2-Negative Breast Cancer